Life
Briefing: Fresh turmoil at the FDA with Prasad’s exit
Strategic angle: Prasad out again, generic Ozempic on its way, and more health news from Morning Rounds
Editorial Staff
1 min read
Updated about 1 month ago
Summary
- Summary pending editorial review.
Key Facts
- Key facts pending editorial review.